3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication

Area of Science:

• Biochemistry
• Pathophysiology
• Endocrinology

Background:

• 3-Deoxyglucosone (3-DG) is synthesized through the Maillard reaction and polyol pathway.
• 3-DG readily forms advanced glycation end products (AGEs), including imidazolone, which is specific to 3-DG.
• Elevated plasma 3-DG levels are observed in diabetes and uremia.

Purpose of the Study:

• To investigate the role of 3-DG in the development of diabetic and uremic complications.
• To explore the relationship between 3-DG, AGE formation, and potential therapeutic interventions.

Main Methods:

• Measurement of plasma and erythrocyte 3-DG levels using gas chromatography-mass spectrometry and high-performance liquid chromatography.
• Immunohistochemistry and immunochemistry using anti-imidazolone antibodies to detect AGEs.
• Assessment of the effects of aldose reductase inhibitors on 3-DG and AGE levels.

Main Results:

• Plasma 3-DG levels are significantly increased in diabetes and uremia, influenced by deproteinization methods.
• Hyperglycemia in diabetes enhances 3-DG synthesis, while decreased catabolism contributes to elevated levels in uremia.
• Elevated 3-DG promotes AGE formation, such as imidazolone, in plasma and erythrocytes.
• Treatment with aldose reductase inhibitors reduced erythrocyte 3-DG and imidazolone levels.

Conclusions:

• 3-Deoxyglucosone plays a significant role in the pathogenesis of diabetic and uremic complications due to its AGE-forming potential and cellular toxicity.
• The findings suggest that 3-DG may be more critical in disease development than previously identified AGEs.
• Aldose reductase inhibitors show promise in mitigating diabetic complications by reducing 3-DG and AGE accumulation.